178 related articles for article (PubMed ID: 19276867)
1. A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
Hirooka Y; Itoh A; Kawashima H; Hara K; Nonogaki K; Kasugai T; Ohno E; Ishikawa T; Matsubara H; Ishigami M; Katano Y; Ohmiya N; Niwa Y; Yamamoto K; Kaneko T; Nieda M; Yokokawa K; Goto H
Pancreas; 2009 Apr; 38(3):e69-74. PubMed ID: 19276867
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Kimura Y; Tsukada J; Tomoda T; Takahashi H; Imai K; Shimamura K; Sunamura M; Yonemitsu Y; Shimodaira S; Koido S; Homma S; Okamoto M
Pancreas; 2012 Mar; 41(2):195-205. PubMed ID: 21792083
[TBL] [Abstract][Full Text] [Related]
3. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Bauer C; Bauernfeind F; Sterzik A; Orban M; Schnurr M; Lehr HA; Endres S; Eigler A; Dauer M
Gut; 2007 Sep; 56(9):1275-82. PubMed ID: 17395611
[TBL] [Abstract][Full Text] [Related]
5. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Mayanagi S; Kitago M; Sakurai T; Matsuda T; Fujita T; Higuchi H; Taguchi J; Takeuchi H; Itano O; Aiura K; Hamamoto Y; Takaishi H; Okamoto M; Sunamura M; Kawakami Y; Kitagawa Y
Cancer Sci; 2015 Apr; 106(4):397-406. PubMed ID: 25614082
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Pei Q; Pan J; Zhu H; Ding X; Liu W; Lv Y; Zou X; Luo H
Int Immunopharmacol; 2014 Mar; 19(1):10-6. PubMed ID: 24389382
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.
Matsui H; Hazama S; Sakamoto K; Shindo Y; Kanekiyo S; Nakashima M; Matsukuma S; Tokuhisa Y; Iida M; Suzuki N; Yoshimura K; Takeda S; Ueno T; Yoshino S; Oka M; Nagano H
Pancreas; 2017 Sep; 46(8):994-1002. PubMed ID: 28697053
[TBL] [Abstract][Full Text] [Related]
8. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
[TBL] [Abstract][Full Text] [Related]
9. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Bauer C; Sterzik A; Bauernfeind F; Duewell P; Conrad C; Kiefl R; Endres S; Eigler A; Schnurr M; Dauer M
Cancer Immunol Immunother; 2014 Apr; 63(4):321-33. PubMed ID: 24384835
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer.
Nakamura M; Wada J; Suzuki H; Tanaka M; Katano M; Morisaki T
Anticancer Res; 2009 Mar; 29(3):831-6. PubMed ID: 19414316
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway.
Pei Q; Pan J; Ding X; Wang J; Zou X; Lv Y
Pancreatology; 2015; 15(3):233-9. PubMed ID: 25937078
[TBL] [Abstract][Full Text] [Related]
13. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Koido S; Homma S; Okamoto M; Takakura K; Mori M; Yoshizaki S; Tsukinaga S; Odahara S; Koyama S; Imazu H; Uchiyama K; Kajihara M; Arakawa H; Misawa T; Toyama Y; Yanagisawa S; Ikegami M; Kan S; Hayashi K; Komita H; Kamata Y; Ito M; Ishidao T; Yusa S; Shimodaira S; Gong J; Sugiyama H; Ohkusa T; Tajiri H
Clin Cancer Res; 2014 Aug; 20(16):4228-39. PubMed ID: 25056373
[TBL] [Abstract][Full Text] [Related]
14. [A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy].
Imai N; Takeda K; Utsunomiya S; Taga M; Kawata N; Ikeda T; Mizutani Y; Hirose K; Ishikawa T; Yoshida S
Gan To Kagaku Ryoho; 2010 Mar; 37(3):527-9. PubMed ID: 20332697
[TBL] [Abstract][Full Text] [Related]
15. Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Miyahara E; Toge T
Hum Cell; 2003 Dec; 16(4):183-9. PubMed ID: 15147038
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Ghansah T; Vohra N; Kinney K; Weber A; Kodumudi K; Springett G; Sarnaik AA; Pilon-Thomas S
Cancer Immunol Immunother; 2013 Jun; 62(6):1083-91. PubMed ID: 23604104
[TBL] [Abstract][Full Text] [Related]
17. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
Soeda A; Morita-Hoshi Y; Makiyama H; Morizane C; Ueno H; Ikeda M; Okusaka T; Yamagata S; Takahashi N; Hyodo I; Takaue Y; Heike Y
Jpn J Clin Oncol; 2009 Dec; 39(12):797-806. PubMed ID: 19797418
[TBL] [Abstract][Full Text] [Related]
18. Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Smith PL; Yogaratnam Y; Samad M; Kasow S; Dalgleish AG
Clin Transl Oncol; 2021 Jan; 23(1):110-121. PubMed ID: 32661823
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Tsukinaga S; Kajihara M; Takakura K; Ito Z; Kanai T; Saito K; Takami S; Kobayashi H; Matsumoto Y; Odahara S; Uchiyama K; Arakawa H; Okamoto M; Sugiyama H; Sumiyama K; Ohkusa T; Koido S
World J Gastroenterol; 2015 Oct; 21(39):11168-78. PubMed ID: 26494971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
